
Where the Money Moved
DropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug Discovery
DropGenie secured Seed+ funding led by Skeleton Key to expand its microfluidics platform for CRISPR workflows, primary cells, and AI-driven drug discovery.
Jesse Landry


























































